EP3064496A4 - Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil - Google Patents
Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil Download PDFInfo
- Publication number
- EP3064496A4 EP3064496A4 EP14856893.4A EP14856893A EP3064496A4 EP 3064496 A4 EP3064496 A4 EP 3064496A4 EP 14856893 A EP14856893 A EP 14856893A EP 3064496 A4 EP3064496 A4 EP 3064496A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- allisartan isoproxil
- amorphous allisartan
- preparation
- pharmaceutical composition
- composition containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XMHJQQAKXRUCHI-UHFFFAOYSA-N propan-2-yloxycarbonyloxymethyl 2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate Chemical compound CCCCC1=NC(Cl)=C(C(=O)OCOC(=O)OC(C)C)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 XMHJQQAKXRUCHI-UHFFFAOYSA-N 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310535073 | 2013-11-01 | ||
| PCT/CN2014/089775 WO2015062498A1 (en) | 2013-11-01 | 2014-10-29 | Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3064496A1 EP3064496A1 (en) | 2016-09-07 |
| EP3064496A4 true EP3064496A4 (en) | 2017-04-12 |
Family
ID=53003359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14856893.4A Withdrawn EP3064496A4 (en) | 2013-11-01 | 2014-10-29 | Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9670184B2 (en) |
| EP (1) | EP3064496A4 (en) |
| JP (1) | JP2016535767A (en) |
| KR (1) | KR20160068979A (en) |
| CN (3) | CN111018841B (en) |
| RU (1) | RU2668267C2 (en) |
| WO (1) | WO2015062498A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115974848B (en) * | 2017-10-24 | 2024-04-02 | 深圳信立泰药业股份有限公司 | Crystal forms of calcium salt of alisartan ester and pharmaceutical composition containing same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1988090A1 (en) * | 2006-02-20 | 2008-11-05 | Shanghai Allist Pharmaceutical., Inc. | Imidazol-5-carboxylic acid derivatives, preparation methods and use therrof |
| EP2157089A1 (en) * | 2007-06-07 | 2010-02-24 | Shanghai Allist Pharmaceutical., Inc. | The therapeutic uses of imidazol-5-carboxylic acid derivatives |
| EP2213669A1 (en) * | 2007-10-11 | 2010-08-04 | Shanghai Allist Pharmaceuticals, Inc. | Crystalline imidazol-5-carboxylic acid derivate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| US5310929A (en) * | 1992-08-06 | 1994-05-10 | E. I. Du Pont De Nemours And Company | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
| AU2003209669A1 (en) * | 2003-02-25 | 2004-09-17 | Hetero Drugs Limited | Amorphous form of losartan potassium |
| CN101195615B (en) * | 2006-12-06 | 2013-03-27 | 深圳市信立泰资产管理有限公司 | Salt of imidazole-carboxylic acid derivant, production method and pharmaceutical composition thereof |
| CN101214242A (en) * | 2007-01-05 | 2008-07-09 | 上海艾力斯医药科技有限公司 | Novel pharmaceutical composition |
| CN101367795B (en) * | 2007-08-17 | 2012-05-02 | 上海艾力斯生物医药有限公司 | Imidazole-5-carboxylic acid derivative and preparation method thereof |
| CN101596189A (en) * | 2008-06-05 | 2009-12-09 | 上海艾力斯生物医药有限公司 | The Pharmaceutical composition that contains imidazole-5-carboxylic acid derivatives |
| CN103012377A (en) * | 2011-09-27 | 2013-04-03 | 江苏艾力斯生物医药有限公司 | Recrystallization method for imidazole-5-carboxylic ester |
| CN103965171A (en) * | 2014-04-30 | 2014-08-06 | 上海艾力斯医药科技有限公司 | Preparation method for Allisartan Isoproxil |
-
2014
- 2014-10-28 CN CN201910658813.2A patent/CN111018841B/en active Active
- 2014-10-28 CN CN201811293433.5A patent/CN109320501B/en active Active
- 2014-10-28 CN CN201410587163.4A patent/CN104610232B/en active Active
- 2014-10-29 RU RU2016119149A patent/RU2668267C2/en active
- 2014-10-29 EP EP14856893.4A patent/EP3064496A4/en not_active Withdrawn
- 2014-10-29 WO PCT/CN2014/089775 patent/WO2015062498A1/en active Application Filing
- 2014-10-29 JP JP2016550922A patent/JP2016535767A/en active Pending
- 2014-10-29 US US15/032,532 patent/US9670184B2/en active Active
- 2014-10-29 KR KR1020167014422A patent/KR20160068979A/en active Search and Examination
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1988090A1 (en) * | 2006-02-20 | 2008-11-05 | Shanghai Allist Pharmaceutical., Inc. | Imidazol-5-carboxylic acid derivatives, preparation methods and use therrof |
| EP2157089A1 (en) * | 2007-06-07 | 2010-02-24 | Shanghai Allist Pharmaceutical., Inc. | The therapeutic uses of imidazol-5-carboxylic acid derivatives |
| EP2213669A1 (en) * | 2007-10-11 | 2010-08-04 | Shanghai Allist Pharmaceuticals, Inc. | Crystalline imidazol-5-carboxylic acid derivate |
Non-Patent Citations (2)
| Title |
|---|
| HANCOCK B C ET AL: "What is the true solubility advantage for amorphous pharmaceuticals?", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 17, no. 4, 1 April 2000 (2000-04-01), pages 397 - 404, XP009086748, ISSN: 0724-8741, DOI: 10.1023/A:1007516718048 * |
| See also references of WO2015062498A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2668267C2 (en) | 2018-09-28 |
| RU2016119149A (en) | 2017-12-04 |
| US20160251338A1 (en) | 2016-09-01 |
| CN109320501B (en) | 2021-06-01 |
| CN111018841A (en) | 2020-04-17 |
| CN104610232B (en) | 2019-09-20 |
| WO2015062498A1 (en) | 2015-05-07 |
| CN111018841B (en) | 2023-04-07 |
| KR20160068979A (en) | 2016-06-15 |
| EP3064496A1 (en) | 2016-09-07 |
| CN109320501A (en) | 2019-02-12 |
| US9670184B2 (en) | 2017-06-06 |
| JP2016535767A (en) | 2016-11-17 |
| CN104610232A (en) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2947084B8 (en) | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof | |
| IL266300B (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
| EP3059238A4 (en) | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | |
| EP3040331A4 (en) | Tetrahydrocyclopentapyrrole derivative and preparation method therefor | |
| HK1222563A1 (en) | Pharmaceutical composition, preparation and uses thereof | |
| EP3022250A4 (en) | Metal-organic materials and method for preparation | |
| EP3048146A4 (en) | Film-forming composition and film-forming method using same | |
| EP3087987A4 (en) | Pharmaceutical composition containing palonosetron | |
| EP2990039A4 (en) | Solid pharmaceutical composition | |
| EP3012256A4 (en) | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition thereof, preparation method and use thereof | |
| EP2924042A4 (en) | Bis- -carboline compound and preparation method, pharmaceutical composition and use thereof | |
| EP3037099A4 (en) | Pharmaceutical composition, preparation method therefor and use thereof | |
| EP3029043A4 (en) | Tricyclic benzoxaborole compound, preparation method therefor, and use thereof | |
| EP3090746A4 (en) | Pharmaceutical composition not containing antioxidant and preparation method therefor | |
| EP3065712A4 (en) | Microparticles, methods for their preparation and use | |
| EP3072895A4 (en) | Phillygenol sulphate and derivative thereof, and preparation method and application thereof | |
| EP2950646A4 (en) | Agrochemical composition, method for its preparation and use thereof | |
| EP3062803A4 (en) | Herbal composition, process for its preparation and use thereof | |
| EP3078659A4 (en) | 3-furyl-2-cyano-2-acrylamide derivative, preparation method therefor, pharmaceutical composition and use thereof | |
| EP3135666A4 (en) | (s)-oxiracetam crystal form iii, preparation method therefor, and application thereof | |
| EP3003298A4 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| EP3090728A4 (en) | Oral composition | |
| EP3090732A4 (en) | Pharmaceutical composition containing clomipramine and preparation method therefor | |
| EP3072896A4 (en) | Taxane compound, and preparation method and use thereof | |
| EP2985338A4 (en) | Fragrance composition and method for producing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20160530 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20170315 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 403/10 20060101AFI20170309BHEP Ipc: A61K 31/4178 20060101ALI20170309BHEP Ipc: A61P 9/12 20060101ALI20170309BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20180305 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20180717 |